Dr Datsons Labs to sell anti-malarial drugs in Yemen

Dr Datsons Labs today said it has inked marketing and supply agreement with Yemen's Al-Mugdh Pharma to sell its anti-malarial drugs in that country.

"Dr Datsons Labs India and Al-Mugdh Pharma of Yemen have signed a licensing, distribution and supply deal, under which the distribution company will market anti-malarial drugs," the company said in a BSE filing.

"The estimated order for Yemen is to the tune of Rs 80 crore," it added.

Commenting on the development, Dr Datsons Labs CEO Sameer Talim said: "The talk between the two companies was going on for last six months and there are certain regulatory aspects that need to be addressed before the commercialisation of the 5 products to be exported to Al-Mugdh Pharma."

The company is looking to widen its product basket to cater to regulated and semi-regulated markets, the statement added.